Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-01-16 @ 9:58 AM
Study NCT ID:
NCT03861793
Status:
COMPLETED
Last Update Posted:
2024-03-05
First Post:
2019-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Sponsor:
Mural Oncology, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-26
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-01
Completion Date Type:
ACTUAL
First Submit Date:
2019-02-25
First Submit QC Date:
None
Study First Post Date:
2019-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-03-01
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-01
Last Update Post Date:
2024-03-05
Last Update Post Date Type:
ACTUAL